Our top pick for
Building a portfolio
Denali Therapeutics Inc is a biotechnology business based in the US. Denali Therapeutics shares (DNLI) are listed on the NASDAQ and all prices are listed in US Dollars. Denali Therapeutics employs 291 staff and has a trailing 12-month revenue of around USD$335.7 million.
|52-week range||USD$18.45 - USD$93.94|
|50-day moving average||USD$60.4277|
|200-day moving average||USD$61.7228|
|Wall St. target price||USD$81|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.63|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Denali Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Denali Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Denali Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 83x. In other words, Denali Therapeutics shares trade at around 83x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Denali Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$71.2 million.
The EBITDA is a measure of a Denali Therapeutics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$335.7 million|
|Operating margin TTM||18.69%|
|Gross profit TTM||USD$123 million|
|Return on assets TTM||3.63%|
|Return on equity TTM||9.21%|
|Market capitalisation||USD$6.3 billion|
TTM: trailing 12 months
There are currently 6.7 million Denali Therapeutics shares held short by investors – that's known as Denali Therapeutics's "short interest". This figure is 0.5% down from 6.7 million last month.
There are a few different ways that this level of interest in shorting Denali Therapeutics shares can be evaluated.
Denali Therapeutics's "short interest ratio" (SIR) is the quantity of Denali Therapeutics shares currently shorted divided by the average quantity of Denali Therapeutics shares traded daily (recently around 683273.56557377). Denali Therapeutics's SIR currently stands at 9.76. In other words for every 100,000 Denali Therapeutics shares traded daily on the market, roughly 9760 shares are currently held short.
However Denali Therapeutics's short interest can also be evaluated against the total number of Denali Therapeutics shares, or, against the total number of tradable Denali Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Denali Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Denali Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.089% of the tradable shares (for every 100,000 tradable Denali Therapeutics shares, roughly 89 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Denali Therapeutics.
Find out more about how you can short Denali Therapeutics stock.
We're not expecting Denali Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Denali Therapeutics's shares have ranged in value from as little as $18.45 up to $93.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Denali Therapeutics's is 1.9303. This would suggest that Denali Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.